Tatva Chintan Pharma Chem IPO GMP History
Tatva Chintan Pharma Chem IPO has been listed on July 29, 2021 at a listing price of ₹2111.85, against the issue price of ₹1083 — a gain of ₹1028.85 (+95%). The GMP peaked at ₹1150 on 28 July 2021 and reached a low of ₹450 on 12 July 2021. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Tatva Chintan Pharma Chem IPO raised ₹500 Cr. through its IPO at a price band of ₹1073 to ₹1083 per share, with a lot size of 13 shares. The IPO was open for subscription from 16 Jul 2021 to 20 Jul 2021.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 7:18 AM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 28 Jul 2021 | ₹ 1150 | ▲ | 106% | — | — |
| 27 Jul 2021 | ₹ 1100 | ▲ | 102% | — | — |
| 26 Jul 2021 | ₹ 1000 | ▲ | 92% | — | — |
| 23 Jul 2021 | ₹ 900 | ▲ | 83% | — | — |
| 22 Jul 2021 | ₹ 800 | — | 74% | — | — |
| 21 Jul 2021 | ₹ 800 | ▲ | 74% | — | — |
| 20 Jul 2021 | ₹ 700 | — | 65% | — | — |
| 19 Jul 2021 | ₹ 700 | ▲ | 65% | — | — |
| 17 Jul 2021 | ₹ 640 | ▲ | 59% | — | — |
| 16 Jul 2021 | ₹ 620 | ▲ | 57% | — | — |
| 15 Jul 2021 | ₹ 600 | ▲ | 55% | — | — |
| 14 Jul 2021 | ₹ 560 | ▲ | 52% | — | — |
| 13 Jul 2021 | ₹ 500 | ▲ | 46% | — | — |
| 12 Jul 2021 | ₹ 450 | — | 42% | — | — |
Tatva Chintan Pharma Chem IPO dates
Key dates from opening to listing. Today is 11 November.
- Open 16 Jul 2021
- Close 20 Jul 2021
- Allotment 26 Jul 2021
- Refund/credit 27 Jul 2021
- Listing 29 Jul 2021
Tatva Chintan Pharma Chem IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹1083 |
|---|---|
| GMP-based estimate (pre-listing) | ₹2233 (+106.2%) |
| Listing gain / loss | +₹1028.85 per share |
| Listing date | 29 Jul, 2021 |
| Actual listing price | ₹2111.85 (+95%) |
Is Tatva Chintan Pharma Chem IPO GMP reliable?
Grey market premium for Tatva Chintan Pharma Chem IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Tatva Chintan Pharma Chem IPO full review for a fundamentals-based assessment before making any grey market trades.
Tatva Chintan Pharma Chem IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Tatva Chintan Pharma Chem IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Tatva Chintan Pharma Chem IPO
Tatva Chintan Pharma Chem Limited was incorporated as a private company on 12 June 1996. It makes structure directing agents, phase transfer catalysts, electrolyte salts for super capacitor batteries, and pharmaceutical and agrochemical intermediates.
It is the largest and only commercial maker of structure directing agents for zeolites in India and the second largest globally, as per the F&S report. It is also one of the leading producers of phase transfer catalysts.
Customers span automotive, petroleum, pharmaceutical, agrochemical, paints, dyes and personal care industries, and include Merck, Bayer AG, Laurus Labs, Navin Fluorine and SRF. Exports gave 76% of revenue from operations in FY 2020. Its plants are at Ankleshwar and Dahej in Gujarat.
The IPO was Rs 500 crore, with Rs 225.00 crore of fresh issue and Rs 275.00 crore of offer for sale. Rs 147.10 crore was planned for expanding the Dahej plant.
Frequently asked
What is the GMP of Tatva Chintan Pharma Chem IPO?
The current Grey Market Premium (GMP) of Tatva Chintan Pharma Chem IPO is ₹ 1150.
What is the Kostak Price of Tatva Chintan Pharma Chem IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Tatva Chintan Pharma Chem IPO is not available.
What is the Subject to Sauda Price of Tatva Chintan Pharma Chem IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Tatva Chintan Pharma Chem IPO?
Tatva Chintan Pharma Chem IPO listed on July 29, 2021 at ₹2111.85, against the issue price of ₹1083 — a gain of +95%.
How did the GMP of Tatva Chintan Pharma Chem IPO trend before listing?
The GMP of Tatva Chintan Pharma Chem IPO was rising in its final days before listing. The GMP peaked at ₹1150 on 28 July 2021. View the day-wise table above for the complete GMP history.
Explore Tatva Chintan Pharma Chem IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
